NCT06336447 VR and Cooled Genicular Nerve Radio Frequency Ablation for Chronic Knee Pain
| NCT ID | NCT06336447 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Northwestern University |
| Condition | Pain, Chronic |
| Study Type | INTERVENTIONAL |
| Enrollment | 62 participants |
| Start Date | 2024-01-12 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 62 participants in total. It began in 2024-01-12 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will examine the impact of virtual reality used in conjunction with sedation compared to sedation alone in patients undergoing watervcooled genicular nerve ablations for chronic knee pain. The goals of the study is to determine the relative efficacy of virtual reality as a distraction modality when used as an adjuvant to procedural sedation compared to sedation alone for procedure related pain. To assess procedural satisfaction, and 1-month pain and functional outcomes.To explore whether virtual reality and lower procedure-related pain scores affect 1-month outcomes. And finally to determine whether demographic and clinical characteristics are associated with outcome measures.
Eligibility Criteria
Inclusion Criteria: * Patients undergoing genicular RFA will be eligible for inclusion in the study * Patients with knee pain, baseline average of \> 4/10 * X-ray evidence of osteoarthritis of the knee * Pain duration of \>6 weeks and no previous knee surgeries * Patients will also only be included who have never undergone a RFA on the affected knee Exclusion Criteria: * Individuals who do not have evidence of osteoarthritis on X-ray, * Secondary gain expected to influence treatment outcomes * Poorly controlled psychiatric condition that could affect outcome (e.g. active substance abuse) or impose a barrier to participation * Chronic opioid use and anticoagulation therapy that cannot be stopped and could warrant a different treatment approach (e.g. phenol ablation) * Severe motion sickness * Seizure disorder * Vision loss * Pregnant * Nursing
Contact & Investigator
Jason Ross, MD
PRINCIPAL INVESTIGATOR
Northwestern Univesity
Frequently Asked Questions
Who can join the NCT06336447 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pain, Chronic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06336447 currently recruiting?
Yes, NCT06336447 is actively recruiting participants. Contact the research team at p-fitzgerald2@northwestern.edu for enrollment information.
Where is the NCT06336447 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT06336447 clinical trial?
NCT06336447 is sponsored by Northwestern University. The principal investigator is Jason Ross, MD at Northwestern Univesity. The trial plans to enroll 62 participants.